ONCS - OncoSec drops 11% despite positive data from TAVO + Merck's Keytruda in metastatic melanoma

OncoSec Medical (ONCS) announces new positive interim data from its KEYNOTE-695 Phase 2b trial evaluating TAVO (tavokinogene telseplasmid), a DNA plasmid-based interleukin-12 (IL-12), in combination with Merck's (MRK) KEYTRUDA (pembrolizumab) in rigorously defined anti-PD1 checkpoint resistant metastatic melanoma patients.TAVO + KEYTRUDA led to a 30% ORR in the first 54 out of 100 planned patients (95%CI [18.0%, 43.6%]) (16/54), much higher than the primary efficacy endpoint of 20% ORR determined by blinded independent review.Complete response rate was 6% (3/54).9% (5/54) patients had 100% reduction of target lesions.ORR was 35% (n=6/17) and 40% (n=6/15) in patients with Stage IV M1c/M1d disease and with prior exposure to ipilimumab, respectively.Median duration of response is currently 12.2 months (95% CI, 5.6-NE).Median study follow-up was 13.5 months.Only 5.4% Grade 3 treatment-related adverse events were observed.The data were will be presented at the Society for Immunotherapy of Cancer's ((SITC)) 35th Anniversary Annual Meeting .OncoSec also announced pre-clinical data showing that CORVax12 triggers an immune

For further details see:

OncoSec drops 11% despite positive data from TAVO + Merck's Keytruda in metastatic melanoma